M&A Deal Summary

Sunovion Pharmaceuticals. Acquires Cynapsus Therapeutics

On August 31, 2016, Sunovion Pharmaceuticals. acquired life science company Cynapsus Therapeutics for 624M USD

Acquisition Highlights
  • This is Sunovion Pharmaceuticals.’s 2nd transaction in the Life Science sector.
  • This is Sunovion Pharmaceuticals.’s largest (disclosed) transaction.
  • This is Sunovion Pharmaceuticals.’s 1st transaction in Canada.
  • This is Sunovion Pharmaceuticals.’s 1st transaction in Ontario.

M&A Deal Summary
Date 2016-08-31
Target Cynapsus Therapeutics
Sector Life Science
Buyer(s) Sunovion Pharmaceuticals.
Deal Type Add-on Acquisition
Deal Value 624M USD
Advisor(s) BofA Securities (Financial)
Borden Ladner Gervais
Troutman Pepper Hamilton Sanders (Legal)

Target

Cynapsus Therapeutics

Toronto, Ontario, Canada
Cynapsus Therapeutics, Inc. is a specialty central nervous system pharmaceutical company that has been developing a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with PD.

Search 200,291 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sunovion Pharmaceuticals.

Marlborough, Massachusetts, United States
Category Company
Founded 1984
Sector Life Science
Employees2,100
Revenue 1.3B USD (2008)
DESCRIPTION

Sunovion is a pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the central nervous system (CNS) and respiratory disease areas and improve the lives of patients and their families.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (Ontario) 1 of 1
Country (Canada) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-09-30 Xopenex Inhalation Solution

United States

Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Sell $45M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-08-19 CNX Therapeutics

London, United Kingdom

CNX Therapeutics is a manufacture and marketing of ethical pharmaceutical drugs. CNX Therapeutics is based in London, United Kingdom.

Sell -
Mergr

Product

Company

Legal